Crinetics Pharmaceuticals Plan to Initiate Paltusotine Phase 3 Study in Carcinoid Syndrome by End of 2024 >CRNX
Crinetics Pharmaceuticals Plan to Initiate Paltusotine Phase 3 Study in Carcinoid Syndrome by End of 2024 >CRNX
Crinetics Pharmaceutics 計劃在 2024 年底之前啓動針對類癌綜合徵的 Paltusotine 3 期研究 >CRNX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊